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Abstract
Background: The avermectins, produced by Streptomyces
avermitilis, are potent anthelminthic agents with a polyketide-
derived macrolide skeleton linked to a disaccharide composed of
two K-linked L-oleandrose units. Eight contiguous genes, avrBC-
DEFGHI (also called aveBI^BVIII), are located within the
avermectin-producing gene cluster and have previously been
mapped to the biosynthesis and attachment of thymidinediphos-
pho-oleandrose to the avermectin aglycone. This gene cassette
provides a convenient way to study the biosynthesis of 2,6-
dideoxysugars, namely that of L-oleandrose, and to explore ways
to alter the biosynthesis and structures of the avermectins by
combinatorial biosynthesis.
Results : A Streptomyces lividans strain harboring a single
plasmid with the avrBCDEFGHI genes in which avrBEDC and
avrIHGF were expressed under control of the actI and actIII
promoters, respectively, correctly glycosylated exogenous aver-
mectin A1a aglycone with identical oleandrose units to yield
avermectin A1a. Modified versions of this minimal gene set
produced novel mono- and disaccharide avermectins. The results
provide further insight into the biosynthesis of L-oleandrose.
Conclusions: The plasmid-based reconstruction of the avr
deoxysugar genes for expression in a heterologous system
combined with biotransformation has led to new information
about the mechanism of 2,6-deoxysugar biosynthesis. The
structures of the di-demethyldeoxysugar avermectins accumulated
indicate that in the oleandrose pathway the stereochemistry at C-3
is ultimately determined by the 3-O-methyltransferase and not by
the 3-ketoreductase or a possible 3,5-epimerase. The AvrF protein
is therefore a 5-epimerase and not a 3,5-epimerase. The ability of
the AvrB (mono-)glycosyltransferase to accommodate different
deoxysugar intermediates is evident from the structures of the
novel avermectins produced. ß 2001 Elsevier Science Ltd. All
rights reserved.
Keywords: avr Gene; Biotransformation; Deoxysugar biosynthesis; Gly-
cosyltransferase; Methyltransferase; Epimerase; Avermectin; Mycarose;
Oleandrose; Combinatorial biosynthesis
1. Introduction
Microorganisms, particularly Actinomycetes, produce
complex natural products that are often decorated with
highly modi¢ed deoxyhexoses. Some of the most impor-
tant antibiotic and antitumor agents, such as the erythro-
mycins, vancomycin, and doxorubicin, lack substantial ac-
tivity without the attached deoxysugars. In contrast, the
series of anthelminthic, 16-membered macrolides produced
by Streptomyces hygroscopicus (milbemycins) and Strepto-
myces thermoachaensis (nemadectins) (Fig. 1) are potent
anthelminithic agents whose structures are closely related
to the avermectins (Streptomyces avermitilis), but do not
have sugars attached. Removing the oleandrose disacchar-
ide attached at the C-13 position of avermectin macrolide
causes a considerable decrease in activity even though it is
not strictly required for activity [1^4]. Recognition of the
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importance of deoxysugars for the bioactivity of antibiot-
ics and antitumor agents has caused a growing interest in
their biosynthesis over the last years [5^8].
Genetic analysis of S. avermitilis has revealed eight
genes, avrBCDEFGHI, that by mutations [1,9^11] and
DNA sequence analysis [12,13] have been assigned to the
biosynthesis of thymidinediphospho (TDP)-oleandrose
and its transfer to avermectin aglycones. Ikeda et al. [13]
have recently named these genes as aveBI^BVIII, respec-
tively. This cluster of contiguous genes provides a conven-
ient system for studying the biosynthesis of neutral 2,6-
dideoxysugars by biotransformation studies in a heterolo-
gous host. The cluster can be restructured on self-replicat-
ing plasmids and expressed with arti¢cial promoters to
investigate the role of the individual genes in oleandrose
biosynthesis and glycosylation of the avermectin agly-
cones. One or more of the genes can be removed from
the plasmid or be replaced with homologs from other bac-
teria to survey the possibility of creating analogs of the
avermectins or other glycosidic metabolites by combining
steps from di¡erent deoxysugar biosyntheses. Although it
is not known whether avermectins with modi¢ed glyco-
sides will have improved properties, the ability to make
manifold changes in the deoxysugar portion of these and
other macrolide antibiotics would certainly further the
quest for new drugs.
To accomplish this goal, the ¢rst step was to outline the
role for each of the avr genes in L-oleandrose biosynthesis,
following the suggestions made by the Merck group [1,12]
and researchers at the Kitasato Institute [2,13,14]. The
biosynthetic pathway of L-oleandrose has a close analogy
to that of the structurally related L-mycarose, as found in
macrolides like the erythromycins [15^18] and the tylosins
[19,20] (Table 1), while L-oleandrose is also found in ole-
andomycin [21]. As illustrated in Fig. 2, the ¢rst two steps
in the oleandrose and mycarose pathways involve conver-
sion of glucose-1-phosphate to its TDP form by a thymi-
dylyl transferase (avrD/aveBII) and then to TDP-4-keto-6-
deoxyglucose by a dehydratase (avrC/aveBIII). These two
steps are common to the formation of all 6-deoxyhexoses
in bacteria [5^8], even though the corresponding genes do
not always lie in the same cluster as the rest of the de-
oxysugar biosynthesis genes for a given secondary metab-
olite, as in case of erythromycin. For oleandrose and my-
carose, C-2 deoxygenation takes place next ^ as shown by
Floss et al. [22] and Liu et al. [20] ^ involving avrG/aveBVI
(encoding a C-2,3-dehydratase) and avrI/aveBVIII (encod-
ing a C-3-ketoreductase) or the homologous eryBVI and
eryBII genes.
The proposed biosynthetic pathway for TDP-L-olean-
drose then modi¢es the TDP-2,6-dideoxy-4-ketoglucose
by the AvrF/AveBV C-(3)5-epimerase, AvrH/AveBVII C-
3-O-methyltransferase, and AvrE/AveBIV C-4-ketoreduc-
tase. For TDP-L-mycarose, the eryBVII and eryBIV genes
control the epimerization and ketoreduction steps [15^18],
whereas eryBIII is believed to encode the C-3-C-methyl-
transferase [18]. The order in which each of these three
reactions occurs is unknown though, as mentioned above,
the 2-deoxygenation step follows 4,6-dehydration [20,22].
Fig. 1. Structures of di¡erent antibiotic and antitumor agents.
Table 1
Functional assignments for genes associated with the biosynthesis of oleandrose in S. avermitilis and mycarose in S. erythraea and S. fradiae
Genea Functionb Amino acid sequence comparisons (% similarity/% identity)
avrB/aveBI glycosyltransferase EryBV (45/21), TylCV (57/39)
avrC/aveBII TDP-glucose 4,6-dehydratase EryGdh (83/69)
avrD/aveBIII glucose-1-phosphate-thymidylyltransferase none in erythromycin genes
avrE/aveBIV TDP-4-ketohexulose reductase EryBIV (66/50), TylCIV(51/30), TylD (50/30)
avrF/aveBV TDP-4-keto-6-deoxyglucose 3-epimerase EryBVII (71/55), TylJ (63/46), TylCVII (58/43)
avrG/aveBVI TDP-4-keto-6-deoxyglucose 2,3-dehydratase EryBVI (66/47)
avrH/aveBVII TDP-6-deoxy-L-hexose 3-O-methyltransferase EryBIII (51/19), TylE (51/25), TylF (46/20)
avrI/aveBVIII TDP-4-keto-6-deoxy-L-hexose 3-ketoreductase EryBII (73/61), TylCII (73/60)
aThe genes are listed in the order they occur in the avermectin gene cluster.
bAs proposed in the references cited in the text.
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We therefore favor the order of reactions as shown in Fig.
2. The same order has also been proposed by Salas and
coworkers in their study of the oleandrose biosynthesis
and glycosyltransferase genes in the oleandomycin pro-
ducer [23]. Raynal et al. [18] have proposed a di¡erent
sequence of reactions for mycarose. They propose that
TDP-4-keto-6-deoxyglucose undergoes epimerization by
EryBVII, followed by 2,3-dehydration (EryBVI) and re-
duction (EryBII), C-methyl transfer (EryBIII) and ¢nally
reduction of the 4-keto group by EryBIV to give TDP-L-
mycarose. Although the TDP group may not be the acti-
vating nucleotide in all such pathways [5,6], Schulman and
coworkers have unambiguously established, by isolation
and bioconversion experiments, that avermectin biosyn-
thesis utilizes TDP-L-oleandrose [24]. Its attachment to
the avermectin aglycone is catalyzed by the glycosyltrans-
ferase AvrB/AveBI while the genes eryBV and tylCV gov-
ern the corresponding steps involving TDP-L-mycarose in
the erythromycin [15^18] and tylosin [20] pathways. With
this information as a guide, we set out to establish how avr
genes could be used to convert avermectin aglycones to
both known and novel avermectin disaccharides.
2. Results
2.1. Restoration of avermectin production in a S. avermitilis
avrCDEFGHI deletion strain
The proposed roles of the avrBCDEFGHI genes in aver-
mectin biosynthesis have rested so far mainly on pheno-
types of S. avermitilis mutants that produce avermectin
aglycones only [4,11,12,25,26] and on the relationship of
the deduced sequences of the gene products to those of
known deoxysugar biosynthesis enzymes [13] (Table 1).
The function of AvrE as a TDP-4-keto-2,6-dideoxyhexose
reductase has been independently established through the
synthesis of 4P-epidaunorubicin and epirubicin [27].
Our ¢rst approach involved creating a single plasmid
(pWHM482; Fig. 3B) holding the eight genes ^ avrBC-
DEFGHI ^ and introducing it by transformation into
S. avermitilis GG1657, a strain lacking all the genes of
L-oleandrose biosynthesis except avrB [9]. The native ar-
rangement of the eight genes [13] suggested that promoters
lie between avrD and avrE, downstream of avrI and up-
stream of avrB. Since the latter promoter could be located
upstream of the ORF1 gene adjacent to avrB [13] and to
ensure expression of avrB, a fragment containing the
3P-end of ORF1 and the genes avrBCDEFGHI was excised
from pVE1190 [25]. AvrB was then orientated downstream
of the strong, constitutive ermE* promoter [28] by cloning
it in pWHM1251 [27], a high copy number plasmid de-
rived from the Escherichia coli/Streptomyces shuttle vector
pWHM3 [29]. In the resulting pWHM482 plasmid avrB
should be expressed under the control of ermE*p and
the seven remaining avr genes under that of their native
promoters, assuming the cloned fragment indeed contains
the avrI promoter. (Expression of the avermectin biosyn-
thesis genes in S. avermitilis is believed to be controlled, all
or in part, by the pathway-speci¢c avrR gene located at
one end of the gene cluster and encoding a putative DNA-
binding protein [13], since deletions or transposon inser-
tions into this region abolish avermectin biosynthesis and
bioconversion of avermectin aglycones [9,11,13,25].)
S. avermitilis GG1657/pWHM482 was grown on solid
growth media and the metabolite pro¢le of the strain,
analyzed by thin-layer chromatography and high perform-
ance liquid chromatography (HPLC) after extraction of
Fig. 2. Proposed pathway for the biosynthesis of L-oleandrose and L-mycarose.
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the plates, proved to be identical to that of the wild-type,
avermectin-producing strain S. avermitilis MA6593.
2.2. Bioconversion of avermectin A1a aglycone to known
avermectins, by recombinant Streptomyces lividans
strains hosting plasmid-borne avrBCDEFGHI genes
To avoid working with the rather di⁄cult to transform
S. avermitilis, our second approach used S. lividans as a
host for the deoxysugar genes. Avermectin A1a aglycone
was exogenously provided within the growth media. The
eight avr genes were rearranged in two gene cassettes on
one plasmid and put under control of the actI and actIII
promoters, respectively. To expedite the cloning work,
pRM5 [30] was modi¢ed as described in Section 5 to cre-
ate pWHM467, having new cloning sites introduced down-
stream of each of the act promoters and the actIII and
actI^VI genes of pRM5 deleted. The genes avrE and avrB
¢rst were oriented in the same direction as avrC and avrD
(pWHM480) so that one promoter could control expres-
sion of all four of these genes. Genes avrIHGF were cloned
into pWHM468 (Table 2) having suitable cloning sites to
create pWHM477. Next, avrBEDC from pWHM480 and
avrIHGF from pWHM477 were inserted into pWHM467
Table 2
Plasmids used in this work
Plasmid Description
pVE1190 11 kb PstI fragment containing avrBCDEFGHI cloned into pVE1053
pWHM465 PacI-HindIII fragment containing the act promoter region cloned from pRM5 into pNEB193
pWHM466 FseI-PacI PCR fragment from pRM5 cloned into pWHM465
pWHM467 HindIII-EcoRI fragment containing act promoter region cloned from pWHM466 into pRM5
pWHM468 polylinker LEH3 cloned into pNEB193 between EcoRI and HindIII sites
pWHM469 2.1 kb BstEII-KpnI fragment containing avrC and avrD cloned from pVE1190 into pWHM468
pWHM470 polylinker LEB4 cloned into pWHM1251 between EcoRI and BamHI sites
pWHM471 1.1 kb AvrII-PstI fragment containing avrE cloned from pWHM470 into pWHM469
pWHM472 1.3 kb XbaI-AvrII PCR fragment containing avrB cloned into pWHM468
pWHM473 1.0 kb SstI-PmlI fragment cloned from pVE1190 into pWHM472 to replace central portion of avrB amplicon
pWHM474 1.3 kb XbaI-AvrII fragment containing avrB cloned from pWHM473 into pWHM471
pWHM476 1.4 kb XhoI-NcoI and 2.8 kb NcoI-NotI fragments from pVE1190, containing avrF, avrG, avrH, and avrI were cloned into
pANT841
pWHM477 4.2 kb BglII-SpeI fragment containing avrF, avrG, avrH, and avrI cloned from pWHM476 into pWHM468
pWHM479 XbaI site was eliminated from pWHM474
pWHM480 4.5 kb PacI-EcoRI fragment containing avrB, avrE, avrD, and avrC cloned from pWHM479 into pWHM467
pWHM481 4.2 kb XbaI-NsiI fragment containing avrI, avrH, avrG, and avrF cloned from pWHM477 into pWHM480
pWHM482 8.7 kb NsiI-HindIII fragment containing part of ORF1 and avrBCDEFGHI cloned from pVE1190 into pWHM1250 at the PstI-
HindIII sites
pWHM485 polylinker LSN5 cloned into pGEM-7zf(+) between SphI and NsiI sites
pWHM488 1.25 kb SpeI-NotI fragment, containing eryBIII cloned from pFL401 into pANT841 between NheI and NotI sites
pWHM2100 2.1 kb XhoI-MscI fragment cloned from pWHM477 into pSE380
pWHM2101 2.1 kb HindIII-PstI fragment cloned from pWHM2100 into pWHM468
pWHM2102 pWHM2101 with in-frame deletion in avrH gene between Bpu11021 and StuI sites
pWHM2103 3.1 kb SstI-MscI fragment cloned from pWHM477 into pSE380
pWHM2104 1.4 kb MscI-XhoI fragment cloned from pWHM2102 into pWHM2103
pWHM2105 2.4 kb MscI-SacI fragment cloned from pWHM2104 into pWHM477
pWHM2106 3.5 kb XbaI-NsiI fragment containing the avrFGI and avrH with an in-frame deletion cloned from pWHM210 into pWHM480,
containing avrBEDC
pWHM2107 XbaI site was eliminated from pWHM471
pWHM2108 3.25 kb PacI-EcoRI fragment cloned from pWHM2107 into pWHM467
pWHM2109 4.2 kb XbaI-NsiI fragment containing avrIHGF cloned from pWHM477 into pWHM2108, containing avrEDC
pWHM2110 In-frame deletion in avrH and avrI between NcoI and MscI sites in pWHM477
pWHM2111 3.2 kb XbaI-NsiI fragment containing avrFG and avrHI with in-frame deletion cloned from pWHM2110 into pWHM480 containing
avrBEDC
pWHM2129 In-frame deletion in avrF in pWHM477 between Eco47III and SstI sites
pWHM2130 3.8 kb XbaI-NsiI fragment containing avrF with in-frame deletion and avrIHG cloned from pWHM2129 into pWHM480,
containing avrBEDC
pWHM2133 3.25 kb PmlI-NsiI fragment, containing avrHGF and avrI with in-frame deletion cloned from pWHM477 into Litmus28
pWHM2134 3.25 kb XbaI-NsiI fragment cloned from pWHM2133 into pWHM480, containing avrBEDC
pWHM2135 3.25 kb XbaI-NsiI fragment cloned from pWHM2133 into pWHM2114, containing avrBDC
pWHM2118 1.25 kb HindIII-EcoRI fragment, containing eryBIII cloned from pWHM488 into pWHM485
pWHM2119 1.25 kb PacI-NsiI fragment, containing eryBIII cloned from pWHM2118 into pKOS025-129
pWHM486 1.55 kb SpeI-PstI fragment, containing eryBV gene cloned into pANT841
pWHM2120 1.55 kb BglII-PstI fragment, containing eryBV cloned from pWHM486 into Litmus28
pWHM2121 1.55 kb XbaI-NsiI fragment, containing eryBV cloned from pWHM2120 into pWHM485
pWHM2122 1.55 kb PacI-NsiI fragment, containing eryBV cloned from pWHM2121 into pKOS025-129
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downstream of the promoters actI and actIII, respectively,
to create pWHM481 (Fig. 3C), which was transformed
into S. lividans K4^114 [31].
To verify that avrB is essential for formation and trans-
fer of L-oleandrose to the aglycone in avermectin biosyn-
thesis, we created plasmid pWHM2109 (Fig. 3C), hosting
genes avrEDCIHGF but missing avrB. The three genes
avrEDC, which had already been reoriented all in the
same direction, were cloned from plasmid pWHM2107
(Table 2) into pWHM467 before adding the avrIHGF cas-
sette in a second step and transforming the resulting plas-
mid pWHM2109 into S. lividans K4^114.
Bioconversion experiments with the S. lividans K4^114/
pWHM481 and S. lividans K4^114/pWHM2109 strains
Fig. 3. Constructs for expression of the avr L-oleandrose deoxysugar genes. (A) Native arrangement of the avrBCDEFGHI genes. (B) and (C) Structure
of plasmid-borne constructs with modi¢ed versions of avr L-oleandrose genes used for biotransformation. Filled wedges oriented in the direction of ex-
pression indicate the genes, open brackets indicate the absence of the gene in the construct, and open circles indicate the promoter regions.
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were carried out in solid growth media, to which puri¢ed
avermectin A1a aglycone was added, and the extracts of
the strains were analyzed by thin-layer chromatography
and HPLC. Fermentation of S. lividans K4^114/
pWHM481 resulted in the production of avermectin A1a
while S. lividans K4^114/pWHM2109 did not show con-
version of the aglycone. These results, in combination with
those gained from the S. avermitilis GG1657/pWHM482
strain, con¢rm that the avrBCDEFGHI genes could re-
store production of TDP-L-oleandrose and support the
belief that avrB is the glycosyltransferase responsible for
attaching the deoxysugar to the avermectin aglycones.
2.3. Bioconversion experiments to identify the functions of
individual avrBCDEFGHI genes
Our next goal was to take a closer look at the proposed
functions of individual genes involved in the biosynthesis
of L-oleandrose. For this we wanted to expand our earlier
approach using the L-oleandrose genes in two cassettes on
a single plasmid by leaving out, deleting, adding or replac-
ing single or multiple genes. By in-frame deletion we elim-
inated genes from the avrIHGF cassette while for manip-
ulation of the avrBEDC genes we used cassettes hosting
only the genes of interest. The plasmids were transformed
Fig. 4. Novel avermectin A1a derivatives from this work.
Fig. 5. (A) Hypothesis for substitution of the function of the AvrI 3-ketoreductase by the 4-ketoreductase AvrE and keto-enol tautomerism. (B) A hy-
pothesis for how the AvrH methyltransferase controls the stereochemistry at C-3.
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into S. lividans K4^114 and once again grown on agly-
cone-enriched solid media to trap any produced deoxysug-
ars in avermectin A1a glycosides.
In a ¢rst experiment we investigated AvrH, supposed to
be a 3-O-methyltransferase. Fermentation of S. lividans
K4^114/pWHM2106 (vavrH ; Fig. 3C), which contains
only the genes avrIGF and avrBEDC, in the presence of
avermectin A1a aglycone led to a number of products with
UV-absorption pattern typical for avermectins. Analytical
and semi-preparative HPLC followed by mass spectrome-
try showed that no avermectin A1a was produced but
indicated the formation of avermectin A1a derivatives
having demethylated mono- and disaccharide moieties
(Table 3). With a conversion rate of less than 5% we con-
centrated on isolating only the main products and were
able to characterize the two novel disaccharide avermec-
tins A1a1 and A1a2 (Fig. 4) by mass spectrometry as well
as one- and two-dimensional (1D and 2D) proton and
carbon nuclear magnetic resonance (NMR) spectroscopy.
A third avermectin derivative, having the same mass as the
avermectins A1a1 and A1a2, was also isolated but not
characterized. The carbon spectra of both compounds
showed 47 signals. Chemical shifts and couplings observed
in the H,H-COSY, HSQC and HMBC spectra con¢rmed
the structure of the aglycone to be that of avermectin A1a,
accounting for 35 carbon signals. For each compound two
anomeric proton signals were identi¢ed and using the 2D-
NMR spectra a total of six carbon signals could be as-
signed for each of the sugars. Small coupling constants
(3.4, 0.8 and 4.1, 1.0 Hz, respectively) con¢rmed that
both were sugars of the L-series and K-glycosidically
linked. Deoxygenated methylene groups were assigned
for position 2 of each sugar and CH groups for positions
3, 4 and 5, followed by a 6-methyl group. The coupling
patterns and constants for the proton signals at C-2, C-3
and C-4 facilitated the assignment of the con¢guration for
each deoxysugar and compound as shown in Fig. 4. The
patterns of the 4-H were particularly helpful ; two large
axial^axial couplings (around 9 Hz) indicated two axial
protons in close proximity (3-H and 5-H) while a large
axial^axial and a smaller equatorial^axial one indicated
axial (5-H) and equatorial (3-H) neighboring protons.
1D-TOCSY and 1D-NOESY NMR veri¢ed the con¢gu-
ration of 3-H of the deoxysugars. The interconnectivities
between sugar^aglycone and sugar^sugar were determined
for avermectin A1a1 by couplings observed in the HMBC
and 2D-NOESY spectrum. For avermectin A1a2 the sug-
ar^sugar connection was concluded from the 2D-NOESY
spectrum while the interglycosidic linkage followed from
the chemical shifts. The structures of the two compounds
Table 3
Functional assignments for genes associated with the biosynthesis of oleandrose in S. avermitilis and mycarose in S. erythraea
Plasmid and genes m/z Possible structures with m/z equals [(M+Na)] ; all modi¢cations within the
sugar moieties
pWHM482a, avrBCDEFGHI 909.4 avermectin A1a (HPLC con¢rmed)
895.5 demethyl-avermectin A1a
881.5 di-demethyl-avermectin A1a
pWHM481b, avrBEDCIIGF 909.5 avermectin A1a (HPLC con¢rmed)
895.5 demethyl-avermectin A1a
881.5 di-demethyl-avermectin A1a
pWHM2109b, avrBEDCIHGF, vavrB ^ ^
pWHM2106b, avrBEDCIGF, vavrH 881.5 avermectins A1a1 and A1a2 and at least one more di-demethyl-avermectin
A1a
751.5 desoleandrose-demethyl-avermectin A1a
pWHM2111b, avrBEDCGF, vavrHI 881.6 avermectins A1a1 and A1a2 (this work) and at least one more di-demethyl-
avermectin A1a
751.6 desoleandrose-demethyl-avermectin A1a
pWHM2134b, avrBEDCHGF, vavrI 909.6 avermectin A1a (HPLC con¢rmed)
895.6 demethyl-avermectin A1a
893.8 demethyl-4-keto-avermectin A1a
879.6 demethyl-(demethyl-4-keto)-avermectin A1a
pWHM2130b, avrBEDCIHG, vavrF 751.6 avermectin A1a3
pWHM2135b, avrBDCHGF, vavrEvavrI 909.6 avermectin A1a (HPLC con¢rmed)
891.6 demethyl-di-4-keto-avermectin A1a
877.6 di-demethyl-di-4-keto-avermectin A1a
763.6 desoleandrose-4-keto-avermectin A1a
749.6 desoleandrose-(demethyl-4-keto)-avermectin A1a
pWHM2106+pWHM2119b, avrBEDCIGF, avrvH+eryBIII 895.6 di-demethyl-3P/3Q-C-methyl-avermectin A1a
881.6 di-demethyl-avermectin A1a
879.6 demethyl-(demethyl-4-keto)-avermectin A1a
751.6 desoleandrose-demethyl-avermectin A1a
^, no bioconversion observed and therefore also no mass data.
aCarried in S. avermitilis GG1657.
bCarried in S. lividans K4^114.
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showed that the hydroxyl groups in position 3 of the de-
oxysugars in both cases had not been methylated, con¢rm-
ing that avrH encodes a 3-O-methyltransferase. Avermec-
tin A1a1 has L-olivose (demethylated L-oleandrose)
attached to the aglycone, followed by a 2,6-dideoxy-L-
ribo-hexopyranose (L-digitoxose) that structurally di¡ers
from L-olivose in its inverted con¢guration of the C-3
stereocenter. In avermectin A1a2 this sugar is directly at-
tached to the aglycone, with L-olivose completing the dis-
accharide moiety (Fig. 4).
For a second and third experiment we created plasmids
hosting the genes avrBEDCHGF (pWHM2134; vavrI) and
avrBEDCGF (pWHM2111; vavrHI), respectively.
pWHM2134 is missing the avrI 3-ketoreductase gene sup-
posed to be involved in the 2-deoxygenation of the deoxy-
sugar, while pWHM2111 has the genes encoding the 3-
ketoreductase and the 3-O-methyltransferase disrupted
(Fig. 3C). HPLC analysis and mass spectrometry of the
metabolites produced by S. lividans K4^114/pWHM2134
showed that avermectin A1a was still being made as well
as avermectin A1a derivatives with mono- or di-demeth-
ylated disaccharides (Table 3). S. lividans K4^114/
pWHM2111 (vavrHI) gave the same overall metabolic
pro¢le as S. lividans K4^114/pWHM2106 (vavrH), pro-
ducing avermectins A1a1 and A1a2. These results, which
mirror those observed for the L-mycarose pathway in Sac-
charopolyspora erythraea [18], let us conclude that the
function of AvrI as a 3-ketoreductase in the 2-deoxygena-
tion steps of the deoxysugar biosynthesis can be either
replaced by a similar ketoreductase from S. lividans or
be substituted by the 4-ketoreductase AvrE after keto-
enol tautomerism (Fig. 5A). In the proposed pathway
the 3-keto group caused by the 2-deoxygenation would
be reduced by the AvrI 3-ketoreductase, followed by epi-
merisation, methyl transfer and ¢nally the reduction of the
4-keto group by AvrE. However, the 3-keto group could,
by keto-enol tautomerism, be moved into the 4-position.
Reduction of the 4-keto group by AvrE would now make
the AvrI 3-ketoreductase redundant.
To take a closer look at the epimerization step that is
responsible for switching from the D- into the L-series of
sugars in this pathway, we constructed pWHM2130, hav-
ing the proposed epimerase gene avrF removed by in-
frame deletion (Fig. 3C). HPLC analysis of the fermenta-
tion extracts of S. lividans K4^114/pWHM2130 showed
only one compound with a typical avermectin UV-absorp-
tion spectrum. Mass spectrometry data indicated an aver-
mectin with a demethylated monosaccharide moiety and
by 1D- and 2D-NMR the compound was characterized to
be avermectin A1a3, with D-olivose as the deoxysugar
(Fig. 4). Thirty-¢ve of the 41 carbon signals observed
could again be assigned to the avermectin A1a aglycone.
The deoxysugar protons 3, 4 and 5 were all observed to be
in axial con¢guration, while the larger axial^axial and
smaller equatorial^axial coupling pattern for the single
anomeric proton (10.0 and 1.7 Hz), caused by the neigh-
boring methylene group, proved this sugar to be D-olivose,
L-glycosidically linked to the aglycone. The only alterna-
tive structure for a deoxysugar having the same character-
istic signals and patterns would have been L-olivose, also
L-glycosidically connected. However, this would raise the
question why L-olivose should have been linked L-glyco-
sidically here when L-sugars in nature are normally found
to be linked K-glycosidically. Avermectins A1a1 and A1a2
(Fig. 4) have L-olivose K-glycosidically connected to the
aglycone. Having D-olivose attached to the aglycone
proves that AvrF is indeed the epimerase of the L-olean-
drose biosynthetic pathway, but acts as a 5- and not a 3,5-
epimerase, as explained further below. The attachment of
D-olivose instead of L-oleandrose to the aglycone also
shows that the AvrB glycosyltransferase is relatively £ex-
ible towards its deoxysugar substrates, as has already been
observed for a number of glycosyltransferases from other
pathways [32^38]. In our case, this £exibility ¢nds a limit
in the inability to interconnect two D-olivose molecules,
which con¢rms the report by Schulman et al. [24] that
two monosaccharides and not a disaccharide are trans-
ferred consecutively to the avermectin aglycone.
An interesting aspect of avermectin A1a3 is the equato-
rial R-con¢guration of the C-4P stereocenter of D-olivose.
In the native biosynthetic pathway AvrE, the 4-ketoreduc-
tase, is thought to catalyze the last step before attaching
the sugar to the aglycone, which creates the equatorial
S-con¢guration at position 4 as in avermectin A1a (Fig.
1). This can be explained in two ways: (i) AvrE is rather
£exible, having its 4-keto sugar substrate located in such
a way that the resulting 4-hydroxyl group is always found
in an equatorial con¢guration. (ii) AvrE is not £exible
and a 4-ketoreductase from S. lividans substitutes for
AvrE, reducing the 4-keto group into the con¢guration
found.
Although we do not have conclusive support for either
hypothesis we favor explanation (ii), since the AvrB gly-
cosyltransferase seems to tolerate both equatorial and ax-
ial hydroxyl groups in position 3 (see avermectins A1a1
and A1a2). We found only avermectin A1a3 but no aver-
mectin glycosylated with D-oliose (L-D-oliose di¡ers from
D-olivose and D-oleandrose by having the 4-hydroxyl
group in the axial instead of equatorial position). This
may indicate that the £exibility of AvrB is limited to
only the three positions in L-deoxysugars. However, in
another experiment where we removed both avrI and
avrE from our eight-member gene set (plasmid
pWHM2135; Fig. 3C), HPLC and mass spectrometry
analysis of fermentation extracts from S. lividans K4^
114/pWHM2135 indicated the production of several deriv-
atives with methylated and demethylated mono- and di-
saccharides attached to the avermectin A1a aglycone (Ta-
ble 5). These compounds were not further characterized
due to low conversion rates. We also observed production
of avermectin A1a in low yield. These results show that
the functions of AvrE and AvrI can be substituted by
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similar enzymes from S. lividans, as already observed for a
related pathway [18].
Further information about how the stereochemistry at
C-3 in the L-oleandrose pathway is controlled and the
function of the AvrF epimerase comes from some of our
earlier experiments above. Both the vavrH and vavrHI
mutant strains produced avermectins having sugar moi-
eties with a 3-R- or 3-S-con¢guration, respectively. The
AvrE 4-ketoreductase and the AvrF epimerase were still
present in both cases. Tight control by either AvrI or
AvrF over the C-3 stereochemistry should have resulted
in deoxysugars with 3-S-con¢guration only and not a mix-
ture of C-3 isomers as observed. This implies that the
AvrH methyltransferase only methylates an equatorial hy-
droxyl group at C-3. In the normal pathway any deoxy-
sugar intermediates with initially axial C-3 hydroxyl
groups would not be methylated until keto-enol tautomer-
ism causes isomerisation of the hydroxyl group (Fig. 5B).
This idea also does not contradict the fact that avermectin
A1a3 is the only product of S. lividans K4^114/
pWHM2130 (vavrF) without traces of a second (or
more) products having the corresponding D-sugar with
an axial instead of an equatorial hydroxyl group at C-3.
Our data show that the AvrB glycosyltransferase has a
limited ability to handle D-deoxysugars and might not be
able to attach two D-sugars to the aglycone.
We conclude from these results that, regardless of the
actual sequence of individual steps in the deoxysugar path-
way, the con¢guration of C-3 is ultimately determined by
the AvrH methyltransferase and not by the AvrF epimer-
ase nor the AvrI 3-ketoreductase. The results also show
that AvrF is a 5-epimerase and not a 3,5-epimerase.
2.4. Bioconversion of avermectin A1a aglycone to novel
avermectins by combining genes from di¡erent
deoxysugar biosynthetic pathways in S. lividans
The above results show that di¡erent deoxysugars can
be attached to the avermectin A1a aglycone by modifying
the biosynthesis of L-oleandrose. We next wanted to ex-
tend this approach by combining di¡erent deoxysugar
pathways with one another. We decided to combine the
avr genes with eryB genes from the closely related mycar-
ose pathway of erythromycin biosynthesis in S. erythraea.
The proposed 3-C-methyltransferase encoded by eryBIII
was chosen for our initial experiments.
Co-transformation of S. lividans K4^114 with plasmids
pWHM2106 (avrBEDCIGF, vavrH) and pWHM2119 (er-
yBIII ; Table 2) could potentially lead to an avermectin
A1a derivative having one or two L-mycarose molecules
attached. A bioconversion experiment with the resulting
strain gave only very low conversion rates (around 0.1%)
to what appeared to be glycosylated avermectin com-
pounds. We did not isolate su⁄cient amounts of any of
these metabolites for NMR analysis, but mass spectrome-
try data indicated the production of an avermectin deriv-
ative with two 2,6-dideoxyhexoses, both bearing addition-
al methyl groups. Since we knew from our earlier
experiment that the gene for the 3-O-methyltransferase,
avrH, had been successfully disrupted in plasmid
pWHM2106, any additional methyl groups had to result
from a 3-C-methyltransferase by EryBIII. Therefore, the
result is consistent with the successful combination of avr
and eryBIII genes.
3. Discussion
We have examined the possibilities of using single and
dual plasmid systems for expression of deoxysugar biosyn-
thesis genes in a heterologous host to both verify the func-
tion of genes that had been assigned on the basis of se-
quence analysis and to produce novel avermectin
glycosides. The 2,6-dideoxysugar L-oleandrose was chosen
for our experiments as the individual steps in its biosyn-
thesis are predictable and the rearrangement of the eight
genes involved in its biosynthesis into two gene cassettes
o¡ered a convenient way to construct various expression
plasmids. The inherent risk is that changes in gene expres-
sion caused by reorganization of some of the avrBCDEF-
GHI genes into arti¢cial operons, or e¡ects of the heter-
ologous host on enzyme activity, would result in low
product yields in the bioconversion experiments. Nonethe-
less, the results obtained prove that the approach, which
builds upon our recent study of the formation anthracy-
cline glycosides by the same method [39], is overall a use-
ful way to produce both known and novel glycosides.
We were able to both restore avermectin production in a
S. avermitilis mutant missing all genes required for the
biosynthesis of L-oleandrose and produce avermectin
A1a in S. lividans using exogenously supplied aglycone.
Modi¢cations of the plasmid-borne avr genes also enabled
us to verify and decode the function of several individual
steps and enzymes in the biosynthesis of L-oleandrose, and
led to the production of three novel avermectins, including
the ¢rst avermectin with a D-deoxysugar attached to its
aglycone. (Although rare, there are at least two other re-
ports where glycosyltransferases recognize both D- and L-
deoxysugars [34,38].) Our results con¢rm that AvrH is the
3-O-methyltransferase of the L-oleandrose biosynthetic
pathway and ultimately determines the con¢guration of
the C-3 stereocenter. AvrF was shown to be not a 3,5-
but a 5-epimerase only. On the basis that AvrE and
AvrI are indeed (3- and 4-)ketoreductases, respectively,
as predicted by gene sequence homologies, we further con-
clude that similar enzymes from S. lividans can substitute
for these two enzymes.
The results also suggest a degree of both substrate £ex-
ibility and in£exibility for the AvrB glycosyltransferase.
AvrB seems to attach and interconnect deoxysugars that
di¡er from its natural substrate by missing the 3-O-methyl
group, having inverted con¢guration at the C-3 stereocen-
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ter, and probably a 3-C- instead of a 3-O-methyl group.
This glycosyltransferase can also attach D-olivose to the
avermectin aglycone, but is unable to interconnect two
D-monosaccharides. This result shows that AvrB transfers
a monosaccharide substrate to the aglycone in two con-
secutive steps instead of a single disaccharide.
4. Signi¢cance
Combinatorial biosynthesis to gain new natural prod-
ucts is greatly expedited when the novel gene combinations
or deletions can be rapidly constructed in vitro and eval-
uated in vivo. This has been most e⁄ciently achieved by
using plasmid vectors and an easily transformable host in
which the introduced genes are well expressed. McDaniel
et al. [40] and Xue et al. [41] have recently demonstrated
the power of this approach, using modular polyketide syn-
thase genes. Deoxysugar biosynthesis genes are equally
suitable, as demonstrated by the macrolide antibiotics
[33,35,36], the angucyclines and tetracenomycins
[32,34,37], glycopeptide antibiotics [42], and the anthracy-
cline epirubicin [27]. Many of these studies have depended
on the construction of a mutation in one or more deoxy-
sugar biosynthesis genes located in the chromosome of the
producing organism, followed by creation of the novel
gene combination through introduction of a plasmid-
borne gene or a gene replacement experiment. Such
work is time consuming and often thwarted when the
host is di⁄cult to transform. Our method, as described
here and earlier [39], avoids some of these problems and
is amenable to creating a large library of recombinants
that can be screened for variations in the biological activ-
ity of known glycosides, or for the formation of novel
glycosides by the bioconversion of a library of aglycones.
The limitation of the glycosyltransferase £exibility or spe-
ci¢city towards either the aglycone and TDP-deoxysugar
substrate might be possible to overcome by e⁄cient muta-
genesis of glycosyltransferase genes using DNA shu¥ing
and other methods [43].
5. Materials and methods
5.1. Bacterial strains and plasmids
E. coli strain DH5K [44] and plasmids pNEB193 and Litmus28
(New England Biolabs) and pANT841, a pUC19 derivative with
additional cloning sites (C. DeSanti, Ohio State University),
pSE380 (Invitrogen), pGEM-7zf(+) (Promega) and pVE1053
[45] were used for routine subcloning. The L-oleandrose biosyn-
thetic genes from S. avermitilis are located on pVE1190 (D. Mac-
Neil, Merck and Co.). The pWHM1251 plasmid containing avrE
was from an earlier study [27]. Low copy number shuttle vector
pRM5 containing the dual act promoter system [30] as well as
pRM5 derivative pKOS025-129 carrying a hygromycin resistance
marker [41], pFL401 containing eryBIII gene, and the S. lividans
K4^114 strain containing a chromosomal deletion of the entire
actinorhodin gene cluster [31] were from Kosan Biosciences. S.
avermitilis v1066 strain was used in which all the oleandrose
genes but avrB were deleted [9]. Plasmids used in this study are
listed in Table 2.
5.2. Media and growth conditions
S. lividans K4^114 was maintained on R2YE agar [46] without
Table 4
13C NMR data of the novel avermectins A1a1, A1a2, A1a3 (relative to
TMS, * in methanol-d4, in chloroform-d1, 125.9 MHz, N, multiplicity
(DEPT))
A1a1* A1a2* A1a2# A1a3*
1 173.0, s 173.0, s 173.0, s 173.8, s
2 46.8, d 46.8, d 45.6, d 46.9, d
3 121.3, d 121.3, d 118.3, d 121.2, d
4 134.5, s 134.8, s 136.0, s 135.2, s
4a 19.9, q 19.9, q 19.9, q 19.9, q
5 78.3, d 78.3, d 77.9, d 78.2, d
5a 57.8, q 57.7, q 57.8, q 55.7, q
6 79.4, d 79.4, d 78.0, d 79.4, d
7 83.0, s 82.0, s 80.5, s 81.1, s
8 141.0, s 141.0, s 140.5, s 141.2, s
8a 68.7, t 68.7, t 68.0, t 68.7, t
9 121.8, d 121.8, d 119.5, d 121.8, d
10 126.5, d 126.4, d 125.5, d 126.2, d
11 138.5, d 138.4, d 136.4, d 139.0, d
12 41.0, d 41.0, d 39.5, d 40.9, d
12a 20.9, q 20.6, q 20.3, q 20.0, q
13 83.9, d 83.5, d 82.0, d 84.0, d
14 136.5, s 136.6, s 134.5, s 137.2, s
14a 15.2, q 15.1, q 15.1, q 15.0, q
15 119.8, d 119.6, d 119.4, d 119.2, d
16 35.0, t 35.1, t 34.3, t 35.1, t
17 70.2, d 70.0, d 68.0, d 70.1, d
18 37.6, t 37.6, t 36.6, t 37.5, t
19 70.0, d 69.8, d 68.0, d 69.9, d
20 42.0, t 42.0, t 40.5, t 42.0, t
21 97.3, s 97.3, s 95.8, s 97.3, s
22 136.5, d 136.5, d 136.3, d 136.6, d
23 129.3, d 129.3, d 127.8, d 129.2, d
24 31.8, d 31.8, d 30.6, d 31.8, d
24a 16.8, q 16.8, q 16.4, q 16.8, q
25 75.9, d 75.9, d 74.8, d 75.9, d
26 36.5, d 36.5, d 35.3, d 36.6, d
26a 13.5, q 13.5, q 13.0, q 13.5, q
27 28.6, t 28.6, t 27.5, t 28.5, t
28 12.6, q 12.5, q 12.1, q 12.5, q
1P 96.2, d 95.9, d 95.0, d 99.1, d
2P 39.5, t 36.1, t 35.2, t 40.8, t
3P 70.3, d 63.6, d 62.7, d 72.5, d
4P 84.3, d 76.6, d 75.1, d 78.7, d
5P 68.7, d 64.3, d 62.7, d 73.2, d
6P 18.7, q 18.1, q 18.2, q 17.2, q
1Q 99.4, d 94.3, d 92.4, d ^
2Q 36.2, t 38.9, t 37.7, t ^
3Q 68.2, d 69.7, d 69.3, d ^
4Q 74.1, d 78.8, d 78.4, d ^
5Q 65.9, d 69.8, d 68.0, d ^
6Q 18.1, q 18.6, q 17.6, q ^
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sucrose and grown in liquid R2YE for preparation of protoplasts
and seed inoculums. Protoplasts were regenerated on R2YE agar
with thiostrepton (obtained from S.L. Lucania, Bristol-Myers-
Squibb, Princeton, NJ, USA) or hygromycin selection at 30 Wg/
ml and 200 Wg/ml in solid medium and 5 Wg/ml and 55 Wg/ml for
liquid medium correspondingly. The E. coli strains were grown in
LB medium [44] supplemented with ampicillin (100 Wg/ml) for
selection of plasmids.
5.3. DNA isolation and in vitro manipulation
Plasmid DNA was isolated from bacterial cells with the Bio
101 Kit (Vista, CA, USA) or by standard procedures [44]. Re-
striction endonuclease digestion and ligation was performed using
standard techniques [44]. DNA fragments for subcloning were
isolated with the Qiaex (Qiagen) gel extraction kit or by phenol:
chloroform extraction [44] from SeaPlaque low melting agarose
Table 5
1H NMR data of the novel avermectins A1a1, A1a2, A1a3 (relative to TMS, * in methanol-d4, in chloroform-d1, 500.6 MHz, N)
A1a1* A1a2* A1a2# A1a3*
2 3.22, m 3.22, m 3.31, m 3.21, m
3 5.47, m 5.47, m 5.38, m 5.47, m
4a 1.79, s 1.78, s 1.81, s 1.78, s
5 3.95a, m 3.93a, m 3.98, m 3.89a, m
5a 3.46, s 3.46, s 3.50, s 3.46, s
6 3.95a, m 3.93a, m 4.03, m 3.89a, m
8a 4.61, dd, 14.3, 2.2 4.62, dd, 14.4, 2.3 4.62, dd, 14.6, 2.1 4.60, dd, 14.5, 2.1
4.65, dd, 14.3, 2.2 4.64, dd, 14.4, 2.3 4.64, dd, 14.6, 2.1 4.64, dd, 14.5, 2.1
9 5.82, ddd, 11.3, 2.2, 2.2 5.82, ddd, 11.1, 2.3, 2.3 5.81, ddd, 11.0, 2.1, 2.1 5.80, ddd, 11.2, 2.1, 2.1
10 5.89, dd, 14.8, 11.3 5.89, dd, 14.9, 11.1 5.76, dd, 14.1, 11.0 5.86, dd, 14.5, 11.2
11 5.72, dd, 14.8, 9.8 5.79, dd, 14.9, 9.8 5.62, dd, 14.1, 9.8 5.65, dd, 14.5, 9.9
12 2.65, ddq, 9.8, 6.9, 2.5 2.65, ddq, 9.8, 6.9, 2.9 2.65, ddq, 9.8, 6.9, 2.9 2.60, ddq, 9.9, 6.8, 3.1
12a 1.16, d, 6.9 1.20, d, 6.9 1.20, d, 6.9 1.12, d, 6.8
13 3.99, s br 4.05, s br 4.05, s br 4.09, s br
14a 1.54, s 1.54, s 1.51, s 1.53, s
15 5.15, dd, 8.0, 4.9 5.22, dd, 9.0, 4.7 5.05, dd, 10.4, 4.7 5.24, dd, 10.7, 4.4
16 2.27, m 2.28, m 2.29, m 2.26, m
17 3.89, m 3.89, m 3.86, m 3.89, m
18e 1.93, ddd, 14.3, 4.2, 4.2 1.96, m 1.74, m 1.92, ddd, 12.7, 4.5, 4.5
18a 0.85, m 0.84, m 0.88, m 0.86, m
19 5.05, dddd, 11.3, 11.3, 4.2, 4.2 5.05, dddd, 11.2, 11.2, 4.6, 4.6 5.36, m 5.04, dddd, 11.8, 11.8, 4.5, 4.5
20e 2.20, ddd, 12.0, 4.2, 1.1 2.17, m 2.03, ddd, 12.0, 4.7, 1.6 2.19, ddd, 11.8, 4.5, 1.6
20a 1.36, m 1.35, m 1.48, m 1.35, m
22 5.75, dd, 10.0, 1.4 5.74, dd, 9.9, 1.7 5.77, dd, 10.0, 1.6 5.75, dd, 10.0, 1.6
23 5.54, dd, 10.0, 2.6 5.54, dd, 9.9, 2.6 5.55, dd, 10.0, 2.7 5.54, dd, 10.0, 2.5
24 2.29, m 2.29, m 2.28, m 2.29, m
24a 0.92, d, 7.2 0.92, d, 7.4 0.91, d, 6.9 0.92, d, 7.2
25 3.48, m 3.48, m 3.47, m 3.46, m
26 1.63, m 1.63, m 1.60, m 1.65, m
26a 0.94, d, 7.0 0.94, d, 6.9 0.93, d, 7.3 0.94, d, 6.7
27 1.48^1.54, m 1.47^1.54, m 1.48^1.54, m 1.48^1.58, m
28 0.98, t, 7.1 0.98, t, 7.4 0.95, t, 7.1 0.99, t, 7.3
1P 4.75, dd, 3.4, 0.8 4.75, dd, 3.5, 0.9 4.83, dd, 3.4, 0.8 4.38, dd, 10.0, 1.7
2Pe 2.08, ddd, 12.9, 5.0, 0.8 2.15, m 2.14, ddd, 14.3, 3.2, 0.8 2.14, ddd, 12.1, 5.2, 1.7
2Pa 1.70, m 1.98, ddd, 14.7, 3.5, 3.5 1.92, ddd, 14.3, 3.4, 3.2 1.60, m
3P 4.02, m 4.25, m 4.27, ddd, 3.2, 3.2, 2.9 3.48, m
4P 3.12, dd, 9.0, 9.0 3.30b 3.29, dd, 9.0, 2.9 2.91, dd, 9.0, 9.0
5P 3.89, dq, 9.0, 6.2 4.29, dq, 9.1, 6.2 4.19, dq, 9.0, 6.4 3.14, dq, 9.0, 6.2
6P 1.28, d, 6.2 1.23, d, 6.2 1.27, d, 6.4 1.26, d, 6.2
1Q 5.28, dd, 4.1, 1.0 5.10, dd, 4.0, 0.9 5.18, dd, 3.7, 0.8 ^
2Qe 2.21, m 2.18, ddd, 14.2, 11.2, 4.0 2.23, ddd, 13.1, 5.0, 0.8 ^
2Qa 1.93, m 1.62, ddd, 14.2, 5.1, 0.9 1.71, m ^
3Q 3.94, m 3.79, ddd, 11.2, 9.1, 5.1 3.95, m ^
4Q 3.19, dd, 9.2, 3.2 2.95, dd, 9.1, 9.1 3.19, dd, 9.2, 9.2 ^
5Q 4.08, dq, 9.2, 6.2 3.65, dq, 9.1, 6.2 3.67, dd, 9.2, 6.4 ^
6Q 1.23, d, 6.2 1.24, d, 6.2 1.30, d, 6.4 ^
aAssignment interchangeable.
bOnly indirectly observed in 2D experiments due to overlapping with solvent.
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(FMC Bioproducts, Rockland, ME, USA). Sequencing reactions
using reverse and forward M13 primers were performed with an
ABI Prism Big Dye terminator cycle sequencing kit at the Uni-
versity of Wisconsin Biotechnology Center. To introduce unique
FseI, NsiI, and XbaI restriction sites downstream of the actIII
promoter in pRM5, two oligonucleotides, PM1 and PO2, were
designed for replacement of the original plasmid DNA. The se-
quence of the original and new DNA is as follows. Original
DNA: 5P-TCCTGCGTGGCCATGTGTTCCcctccCTGCCTCG-
TGGTCC-3P ; PM1: 5P-TCCTGGCCGGCCATGCATTCCcctcc-
CTGTCTAGAGGTCC-3P. Changes are shown in bold italic with
the actIII ribosome-binding site (rbs) in lower case. The second
oligonucleotide, PO2, was distal to the PacI site in pRM5 down-
stream of the left promoter to allow PacI digestion of the PCR
product. The sequence of this primer was identical to that of
pRM5: 5P-CCCAGTCACGACGTTGTAAAACGACGGCC-3P.
A new polylinker, LEH3, for pNEB193 was created as a syn-
thetic oligonucleotide containing rbs and the following internal
sites: BstEII, KpnI, PstI, AvrII, XbaI, PacI, BglII, SpeI, NsiI.
Top strand: 5P-AATTCGGTAACCGGTACCCTGCAGCCTA-
GGTCTAGAGGAGGATTAATTAAAGATCTACTAGTATG-
CATA-3P ; bottom strand: 3P-GCCATTGGCCATGGGAC-
GTCGGATCCAGATCTCCTCCTAATTAATTTCTAGATGA-
TCATACGTATTCGA-5P. The LEH3 polylinker was used to
replace the original polylinker of pNEB193 by cloning into the
EcoRI and HindIII sites to create pWHM468. Similarly, a syn-
thetic DNA linker, LEB4, containing rbs and the internal sites
XbaI and AvrII were cloned between the EcoRI and BamHI sites
of the polylinker of pWHM1251 to create pWHM472; top
strand: 5P-AATTCTCTAGACCTAGGGGAGGAG-3P ; bottom
strand: 3P-GAGATCTGGATCCCCTCCTCCTAG-5P. A new
polylinker, LSN5, for pGEM-7zf(+) was created as a synthetic
oligonucleotide containing rbs and the following internal sites:
PacI, HindIII, MscI, EcoRI, XbaI, BglII, and PstI. Top strand:
5P-CTTAATTAAGGAGGAAAGCTTTGGCCAGAATTCTCT-
AGAAGATCTCTGCAGATGCA-3P ; bottom strand: 3P-GT-
ACGAATTAATTCCTCCTTTCGAAACCGGTCTTAAGAGA-
TCTTCTAGAGACGTCT-5P. The LSN5 polylinker was used to
replace the original polylinker of pGEM-7zf(+) by cloning into
SphI and NsiI sites to create pWHM485.
To create plasmid pWHM472 a 1.3 kb PCR amplicon for avrB
with XbaI-AvrII sites was made (Easy Start Kit, Molecular Bio-
Products, Inc.). The following two primers were used: PO6: 5P-
TTTTCTAGACAGTGAGAGATGTCAGATCA-3P and PO7:
5P-TTTCCTAGGAACCCTGTGGGAGCCACTCA-3P to intro-
duce the needed XbaI and AvrII sites. Ampli¢cation was made
using the Easy Start Kit. The reaction mixture was incubated at
94‡C for 2 min and then 30 cycles of denaturing (94‡C, 1 min),
annealing (55‡C, 1.5 min) and elongation (70‡C, 2 min) followed
by a cycle of elongation (70‡C, 10 min).
5.4. Modi¢cation of vector pRM5 for in vivo expression of
avermectin L-oleandrose genes
The shuttle vector pRM5 has been used for expressing polyke-
tide synthase genes in Streptomyces coelicolor strains that lack the
entire act biosynthetic cluster [30]. To make this vector more
useful for cloning and expression of Streptomyces genes, the fol-
lowing modi¢cations were done as described below: (a) part of
actIII was deleted to ensure that the ActIII protein would not be
expressed, (b) the act genes downstream of the actI promoter
were deleted, and (c) new cloning sites were introduced down-
stream of both the actI and actIII promoters. The HindIII-PacI
fragment containing the actI/actIII promoter region was cloned
into pNEB193 to facilitate manipulation and to provide an
EcoRI site next to the PacI site (pWHM465, Table 2). A PCR
fragment was ampli¢ed using primers PM1 and PO2 (above) to
introduce unique FseI, NsiI, and XbaI sites downstream of the
actIII promoter. The new FseI site allowed the deletion of about
one-third of actIII by cutting a single internal FseI site followed
by religation. The PCR product was digested with FseI and PacI
and cloned into pWHM465 to yield pWHM466 (Table 2). The
HindIII-EcoRI fragment from pWHM466 containing the actII-
ORF4 activator gene and act promoter region was used to re-
place the act genes in pRM5 to give pWHM467. Ampli¢cation
was made as described above.
5.5. Construction of plasmids for expression of the avrBCDEFGHI
genes
Plasmid pWHM482 was constructed using the Streptomyces
expression vector pWHM1250 and the native L-oleandrose bio-
Table 6
HMBC couplings of avermectin A1a1 in methanol-d4 (N, relative to
TMS)
Position 1H 13C Position
4a 1.79 78.3 5/6
121.3 3
134.5 4
5a 3.46 78.3 5/6
5/6 3.95 46.8 2
12a 1.16 41.0 12
83.9 13
138.5 11
14a 1.54 83.9 13
119.8 15
136.4 14
18a 0.85 70.2 17
24a 0.92 31.8 24
75.9 25
136.5 22
26a 0.94 28.6 27
36.5 26
75.9 25
28 0.98 36.5 26
28.6 27
4P 3.12 68.7 5P
99.4 1Q
6P 1.28 84.3 4P
68.7 5P
2Qa 1.93 68.2 3Q
4Q 3.19 65.9 5Q
6Q 1.23 74.1 4Q
65.9 5Q
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synthetic gene cluster avrBDCEFGHI from S. avermitilis. The
cluster, which contained a C-terminal portion of ORF1, was sub-
cloned as an 8.7 kb NsiI-HindIII fragment from pVE1190 behind
the ermE* promoter of pWHM1250.
A plasmid, pWHM481, was constructed in which the eight avr
genes were divided into two groups: genes avrB, avrE, avrD and
avrC in one, avrI, avrH, avrG and avrF in the other (Fig. 3C). The
two sets of genes are each oriented in opposite directions and
expressed under control of the actI and actIII promoters. The
avrB and avrE genes were reoriented from the native arrangement
into the same direction as avrC and avrD as follows: the poly-
linker LEH3 (see above) was synthesized and cloned into
pNEB193 to create pWHM468 (Table 2), then avrD and avrC
were cloned from pVE1190 as a 2.1 kb fragment into pWHM468
between the KpnI and BstEII sites to create pWHM469 (Table 2).
The polylinker LEB4 containing a rbs and novel XbaI and AvrII
restriction sites was introduced upstream of the start codon of
avrE between the EcoRI and BamHI sites of pWHM1251 [27] to
create pWHM470. The AvrII-PstI fragment containing the entire
avrE gene was excised from pWHM470 and cloned into
pWHM469 to create pWHM471 (Table 2). The avrB gene was
ampli¢ed from pVE1190 by PCR with the primers PO6 and PO7
(above) as a 1.3 kb XbaI-AvrII fragment and cloned into
pWHM468 to create pWHM472. The central portion of this frag-
ment between SstI and PmlI sites in pWHM472 was replaced
with a non-ampli¢ed fragment from pVE1190 to produce
pWHM473 (Table 2). The remaining ends of the avrB gene
were sequenced to verify authenticity. The XbaI-AvrII fragment
containing avrB was cloned from pWHM473 into pWHM471 to
create pWHM474 (Table 2). The XbaI site was eliminated from
pWHM474 to create pWHM479. The genes avrB, avrC, avrD and
avrE, all oriented in the same direction, were cloned as a PacI-
EcoRI fragment from pWHM479 into pWHM467 under control
Table 7
H,H-COSY couplings of avermectin A1a1 in methanol-d4 (N, relative to
TMS)
Position 1H 1H Position
2 3.22 1.79 4a
3.95 5/6
5.47 3
3 5.47 1.79 4a
3.22 2
3.95 5/6
4a 1.79 3.22 2
5.47 3
5/6 3.95 5.47 3
6 3.95 3.22 2
8a 4.61, 4.65 5.82 9
9 5.82 4.61, 4.65 8a
10 5.89 5.72 11
11 5.72 2.65 12
5.89 10
12 2.65 5.72 11
1.16 12a
12a 1.16 2.65 12
14a 1.54 5.15 15
15 5.15 1.54 14a
2.27 16
16 2.27 3.89 17
5.15 15
17 3.89 0.85 18a
2.27 16
18e 1.93 0.85 18a
2.20 20e
5.05 19
18a 0.85 1.93 18e
3.89 17
5.05 19
19 5.05 0.85 18a
1.36 20a
1.93 18e
2.20 20e
20e 2.20 1.36 20a
1.93 18e
5.05 19
20a 1.36 2.20 20e
5.05 19
22 5.75 2.29 24
5.54 23
23 5.54 2.29 24
5.75 22
24 2.29 1.63 26
0.92 24a
3.48 25
5.54 23
5.75 22
24a 0.92 2.29 24
25 3.48 2.29 24
26 1.63 0.94 26a
2.29 24
26a 0.94 1.63 26
27 1.48^1.54 0.98 28
28 0.98 1.48^1.54 27
1P 4.75 1.70 2Pa
2Pe 2.08 1.70 2Pa
4.02 3P
2Pa 1.70 2.08 2Pe
4.02 3P
4.75 1P
Table 7 (continued)
Position 1H 1H Position
3P 4.02 1.70 2Pa
2.08 2Pe
3.12 4P
4P 3.12 3.89 5P
4.02 3P
5P 3.89 1.28 6P
3.12 4P
6P 1.28 3.89 5P
1Q 5.28 1.93 2Qa
2.21 2Qe
2Qe 2.21 1.93 2Qa
5.28 1Q
2Qa 1.93 2.21 2Qe
5.28 1Q
3Q 3.94 3.19 4Q
4Q 3.19 1.23 6Q
3.94 3Q
4.08 5Q
5Q 4.08 1.23 6Q
3.19 4Q
6Q 1.23 3.19 4Q
4.08 5Q
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of the actI promoter to create pWHM480. The remaining genes
avrF, avrG, avrH, and avrI were cloned from pVE1190 as two
fragments (XhoI-NcoI and NcoI-NotI) into pANT841 to give
pWHM476 (Table 2). This set was cloned from pWHM476 as
a 4.2 kb BglII-SpeI fragment into pWHM468 to create
pWHM477, before being introduced into pWHM480 as a 4.2
kb XbaI-NsiI fragment under control of the actIII promoter to
create pWHM481 (Table 2; Fig. 3C).
Modi¢ed versions of pWHM481 carrying an incomplete or
partially disrupted set of avr sugar genes were generated. A plas-
mid with an in-frame deletion in the avrH gene was constructed
as follows. A 2.1 kb XhoI-MscI fragment, containing the genes
avrI and avrH and part of avrG was subcloned from pWHM477,
containing genes avrIHGF, into pSE380 to create pWHM2100.
The same 2.1 kb HindIII-PstI fragment from pWHM2100 was
cloned into pWHM468 to create pWHM2101. An in-frame dele-
tion removing a 693 bp fragment from avrH between Bpu11021
and StuI sites was created in pWHM2101 to give pWHM2102. A
3.1 kb SstI-MscI fragment from pWHM477 was cloned into
pSE380 to create pWHM2103. To replace the original avrH
gene, a 1.4 kb MscI-XhoI fragment from pWHM2102 with an
in-frame deletion in avrH was cloned into pWHM2103 to create
pWHM2104. To get plasmid 2105 with avrIGFavrvH, a 2.4 kb
MscI-SacI fragment from pWHM2104 was cloned into
pWHM477. Finally, to get a plasmid containing the avrIG-
FavrvH and avrBEDC cassettes, a 3.5 kb XbaI-NsiI fragment
from pWHM2105 was cloned into pWHM480 to create
pWHM2106 (Table 2; Fig. 3C).
To construct a plasmid without the avrB gene, the XbaI site
was eliminated from pWHM471, containing the avrEDC genes,
to create pWHM2107, while a 3.25 kb PacI-EcoRI fragment from
pWHM2107 was cloned into pWHM467 to create pWHM2108.
A 4.2 kb XbaI-NsiI fragment from pWHM477, containing genes
avrIHGF, was cloned into pWHM2108, containing avrEDC, to
create pWHM2109 (Table 2; Fig. 3C).
A plasmid with an in-frame deletion in the avrI and avrH genes
was constructed as follows. An in-frame deletion removed a 999
bp fragment from the avrI and avrH genes between the NcoI and
MscI sites in pWHM477 to give pWHM2110. A 3.2 kb XbaI-NsiI
fragment, containing the vavrI and vavrH genes and avrG and
avrF was cloned into pWHM480, containing avrBEDC, to create
pWHM2111 (Table 2; Fig. 3C).
A plasmid with deletion in avrF gene was constructed as fol-
lows. An in-frame deletion removing a 369 bp fragment from
avrF gene between Eco47III and SstI sites was created in
pWHM477, containing the avrIHGF cassette, to give
pWHM2129. From the latter plasmid, a 3.8 kb XbaI-NsiI frag-
ment, containing the avrIHG genes and vavrF gene, was cloned
into pWHM480, containing the avrBEDC cassette, to create
pWHM2130 (Table 2; Fig. 1B).
A plasmid with an in-frame deletion in the avrI gene was con-
structed using a 3.25 kb PmlI-NsiI fragment, containing genes
avrHGF and part of avrI, cloned from pWHM477 into Litmus28
to create pWHM2133, containing an in-frame deletion in the avrI
gene. A 3.25 kb XbaI-NsiI fragment from pWHM2133 was
Table 8
2D-NOESY couplings of avermectin A1a1 in methanol-d4 (N, relative to
TMS)
Position 1H 1H Position
2 3.22 5.47 3
3 5.47 1.79 4a
3.22 2
4a 1.79 5.47 3
3.95 5/6
5/6 3.95 1.79 4a
9 5.82 5.72 11
11 5.72 5.82 9
12 2.65 1.54 14a
3.99 13
12a 1.16 3.99 13
13 3.99 1.16 12a
1.54 14a
2.65 12
14a 1.54 2.27 16
2.65 12
3.99 13
16 2.27 1.54 14a
18e 1.93 0.85 18a
18a 0.85 1.93 18e
20e 2.20 1.36 20a
20a 1.36 2.20 20e
22 5.75 0.92 24a
2.29 24
5.54 23
23 5.54 5.75 22
24 2.29 0.92 24a
0.94 26a
5.75 22
24a 0.92 2.29 24
5.75 22
26 1.63 0.94 26a
26a 0.94 1.63 26
2.29 24
2Pe 2.08 4.02 3P
3P 4.02 2.08 2Pe
4P 3.12 5.28 1Q
1.28 6P
5P 3.89 1.28 6P
6P 1.28 5.28 1Q
3.12 4P
3.89 5P
1Q 5.28 1.28 6P
1.93 2Qa
3.12 4P
2Qe 2.21 1.93 2Qa
2Qa 1.93 2.21 2Qe
3.19 4Q
3.94 3Q
5.28 1Q
3Q 3.94 1.93 2Qa
3.19 4Q
4Q 3.19 1.23 6Q
1.93 2Qa
3.94 3Q
4.08 5Q
5Q 4.08 1.23 6Q
3.19 4Q
6Q 1.23 3.19 4Q
4.08 5Q
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cloned into pWHM480, containing the avrBEDC genes, to create
pWHM2134 (Table 2; Fig. 3C).
A plasmid with an in-frame deletion in the avrI gene and with-
out the avrE gene was constructed as follows. A 3.25 kb XbaI-
NsiI fragment from pWHM2133, containing genes avrHGF and
the vavrI gene, was cloned into pWHM2114, already containing
genes avrBDC, to create pWHM2135 (Table 2; Fig. 3C).
To introduce additional genes (eryBIII, and eryBV) a two-plas-
mid system was used. pWHM467 contained the avr genes and
thiostrepton resistance gene while pKOS025-129 carried the addi-
tional genes and hygromycin resistance marker. A derivative of
pKOS025-129, containing the gene eryBIII, was constructed by
cloning a 1.25 kb SpeI-NotI fragment, containing eryBIII, from
pFL401 into pANT841 between the sites NheI and NotI to create
pWHM488. A 1.25 kb HindIII-EcoRI fragment, containing ery-
BIII from pWHM488, was next cloned into pWHM485 to give
pWHM2118. A 1.25 kb PacI-NsiI fragment from pWHM2118
was cloned into pKOS025-129 under control of the actI pro-
moter, creating pWHM2119.
5.6. Bioconversion of avermectin aglycones and product analysis
Avermectin aglycones were produced by shaken-£ask cultures
of the S. avermitilis v1066 strain which has a 16 kb deletion of all
the TDP-oleandrose biosynthesis genes except avrB [25], or
S. avermitilis MA6057a, a mutant mapped to a deletion of the
avrF gene, using previously described seed [47] and liquid pro-
duction media [48].
Avermectin A1a aglycone was puri¢ed and characterized in the
following way. The crude extract residues obtained by methanol
and ethyl acetate extraction of recovered mycelia were fraction-
ated over silica gel using a £ash funnel method: 350 mg of crude
extract residue coated on 5 g of silica gel in a 4 cm diameter, 4 cm
Table 10
H,H-COSY couplings of avermectin A1a2 in methanol-d4 (N, relative to
TMS)
Position 1H 1H Position
2 3.22 1.78 4a
3 5.47 1.78 4a
4a 1.78 3.22 2
5.47 3
10 5.89 5.79 11
11 5.79 2.65 12
5.89 10
12 2.65 1.20 12a
5.79 11
12a 1.20 2.65 12
15 5.22 2.28 16
16 2.28 3.89 17
5.22 15
17 3.89 0.84 18a
2.28 16
18e 1.96 0.84 18a
18a 0.84 1.96 18e
3.89 17
5.05 19
19 5.05 0.84 18a
1.35 20a
20e 2.17 1.35 20a
20a 1.35 2.17 20e
5.05 19
22 5.74 5.54 23
23 5.54 5.74 22
24 2.29 0.92 24a
3.48 25
24a 0.92 2.29 24
3.48 25
25 3.48 0.92 24a
2.29 24
26 1.63 0.94 26a
26a 0.94 1.63 26
27 1.47^1.54 0.98 28
28 0.98 1.47^1.54 27
1P 4.75 1.98 2Pa
2.15 2Pe
2Pe 2.15 1.98 2Pa
4.25 3P
4.75 1P
2Pa 1.98 2.15 2Pe
4.75 1P
3P 4.25 2.15 2Pe
5P 4.29 1.23 6P
6P 1.23 4.29 5P
1Q 5.10 1.62 2Qa
2Qe 2.18 1.62 2Qa
2Qa 1.62 2.18 2Qe
3.79 3Q
5.10 1Q
3Q 3.79 1.62 2Qa
2.95 4Q
4Q 2.95 3.65 5Q
3.79 3Q
5Q 3.65 1.24 6Q
2.95 4Q
6Q 1.24 3.65 5Q
Table 9
HMBC couplings of avermectin A1a2 in methanol-d4 (N, relative to
TMS)
Position 1H 13C Position
4a 1.78 121.3 3
134.8 4
5a 3.46 78.3 5/6
12a 1.20 41.0 12
83.5 13
138.4 11
14a 1.54 83.5 13
119.6 15
136.6 14
24a 0.92 31.8 24
75.9 25
26a 0.94 28.6 27
36.5 26
75.9 25
28 0.98 28.6 27
36.5 26
6P 1.23 64.3 5P
76.6 4P
6Q 1.24 69.8 5Q
78.8 4Q
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high scintered glass funnel was eluted with three successive meth-
ylene chloride washes, followed by elution with a 5% step gra-
dient of ethyl acetate in methylene chloride and fractions of 20 ml
were collected. The appropriate fractions from three such puri¢-
cations were combined to give one sample of enriched avermectin
A1a aglycone, which was further puri¢ed by semi-preparative
HPLC using solvent gradient system 1 (see below). Alternatively
avermectin A1a aglycone was isolated directly out of the crude
extract residue in two puri¢cation steps by semi-preparative
HPLC (solvent gradient system 2). The resulting puri¢ed material
was analyzed by ESI-LRMS and ESI-HRMS as well as by HPLC
comparison with authentic avermectin aglycone obtained through
acid hydrolysis of a concentrated crude extract of avermectins
obtained from fermentation of S. avermitilis ATCC 31272 (kindly
provided by R.W. Fedechko and K. Stutzmann-Engwall at Chas.
P¢zer and Co.).
For bioconversion experiments using S. lividans K4^114 har-
boring the pWHM481, pWHM2106, pWHM2109, pWHM2111,
pWHM2130, pWHM2134, or pWHM2135 plasmids (Fig. 3C), or
both pWHM2106 and pWHM2119 or both pWHM2109 and
pWHM2122, transformants were grown on solid R2YE without
sucrose with exogenous A1a avermectin aglycone (10 Wg/ml).
Antibiotics were added to the media as follows: for transform-
ants carrying pWHM481, pWHM2106, pWHM2109,
pWHM2111, pWHM2130, pWHM2134 and pWHM2135, thio-
strepton at 30 Wg/ml; for transformants carrying pWHM2106 and
pWHM2119 or pWHM2109 and pWHM2122, thiostrepton at 30
Wg/ml and hygromycin at 200 Wg/ml. After 5 days of incubation,
avermectin metabolites were extracted from chopped solid R2YE
using equal volumes of ethyl acetate, concentrated by evapora-
tion under a stream of nitrogen to give an oily residue, which was
resuspended in methanol.
Our initial approach was to grow three agar plates of each
strain. The methanol extracts of these were ¢rst analyzed by
HPLC using the analytical system (see below) and those metab-
olites that showed the typical avermectin UV-absorption spec-
trum were isolated by semi-preparative HPLC (systems 1 and
3) before further being analyzed by electrospray mass spectrom-
etry. The strains that were investigated in the above described
manner are shown with positive ion ESI-MS m/z data for metab-
olites isolated from the respective strains and what possible prod-
uct this (these) mass(es) might re£ect in Table 3.
5.7. Isolation and characterization of avermectins A1a1, A1a2 and
A1a3
Under the conditions described above S. lividans K4^114/
pWHM2106, S. lividans K4^114/pWHM2111 and S. lividans
K4^114/pWHM2130 strains were grown on 3 l, 1.5 l and 1.5 l
of solid media (8.5 cm diameter plates, with each plate holding
Table 12
HMBC couplings of avermectin A1a2 in chloroform-d1 (N, relative to
TMS)
Position 1H 13C Position
4a 1.81 118.3 3
136.0 4
5/6 3.98 78.0 5/6
5a 3.50 77.9 5/6
12a 1.20 39.5 12
82.0 13
136.4 11
14a 1.51 82.0 13
119.4 15
134.5 14
18a 0.88 68.0 17
24a 0.91 30.6 24
74.8 25
136.3 22
26a 0.93 27.5 27
35.3 26
28 0.95 27.5 27
35.3 26
6P 1.27 62.7 3P
75.1 4P
6Q 1.30 68.0 5Q
78.4 4Q
Table 11
2D-NOESY couplings of avermectin A1a2 in methanol-d4 (N, relative to
TMS)
Position 1H 1H Position
3 5.47 1.78 4a
4a 1.78 5.47 3
5/6 3.93 3.46 5a
5a 3.46 3.93 5
10 5.89 5.79 11
11 5.79 5.89 10
12 2.65 1.54 14a
12a 1.20 4.05 13
13 4.05 1.20 12a
14a 1.54 2.65 12
18e 1.96 0.84 18a
18a 0.84 1.96 18e
20e 2.17 1.35 20a
20a 1.35 2.17 20e
22 5.74 0.92 24a
5.54 23
23 5.54 5.74 22
24 2.29 0.92 24a
24a 0.92 2.29 24
3.48 25
5.74 22
25 3.48 0.92 24a
27 1.47^1.54 0.98 28
28 0.98 1.47^1.54 27
1P 4.75 1.98 2Pa
2.15 2Pe
2Pe 2.15 4.75 1P
1.98 2Pa
2Pa 1.98 2.15 2Pe
4.75 1P
5P 4.29 1.23 6P
5.10 1Q
6P 1.23 4.29 5P
1Q 5.10 4.29 5P
2Qe 2.18 1.62 2Qa
2Qa 1.62 2.18 2Qe
5Q 3.65 1.24 6Q
6Q 1.24 3.65 5Q
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Table 14
2D-NOESY couplings of avermectin A1a2 in chloroform-d1 (N, relative
to TMS)
Position 1H 1H Position
3 5.38 1.81 4a
4a 1.81 5.38 3
12 2.65 1.20 12a
1.51 14a
4.05 13
12a 1.20 2.65 12
13 4.05 2.65 12
14a 1.51 2.65 12
15 5.05 2.29 16
16 2.29 5.05 15
19 5.36 2.03 20e
20e 2.03 1.48 20a
5.36 19
20a 1.48 2.03 20e
1P 4.83 1.92 2Pa
2.14 2Pe
2Pe 2.14 1.92 2Pa
4.83 1P
2Pa 1.92 2.14 2Pe
4.83 1P
3P 4.27 3.29 4P
4P 3.29 1.27 6P
4.27 3P
5P 4.19 1.27 6P
6P 1.27 4.19 5P
3.29 4P
1Q 5.18 1.71 2Qa
2.23 2Qe
2Qe 2.23 5.18 1Q
3.95 3Q
2Qa 1.71 5.18 1Q
3Q 3.95 2.23 2Qe
5Q 3.67 1.30 6Q
6Q 1.30 3.67 5Q
Table 13
H,H-COSY couplings of avermectin A1a2 in chloroform-d1 (N, relative
to TMS)
Position 1H 1H Position
2 3.31 1.81 4a
3.98 5/6
5.38 3
3 5.38 1.81 4a
3.31 2
3.98 5/6
4a 1.81 3.31 2
5.38 3
5/6 3.98 3.31 2
5.38 3
8a 4.62, 4.64 5.81 9
9 5.81 4.62, 4.64 8a
11 5.62 2.65 12
12 2.65 1.20 12a
5.62 11
4.05 13
12a 1.20 2.65 12
13 4.05 2.65 12
2.29 16
5.05 15
15 5.05 2.29 16
4.05 13
16 2.29 3.86 17
4.05 13
5.05 15
17 3.86 2.29 16
0.88 18a
18e 1.74 0.88 18a
18a 0.88 1.74 18e
3.86 17
5.36 19
19 5.36 1.48 20a
2.03 20e
0.88 18a
20e 2.03 1.48 20a
5.36 19
20a 1.48 2.03 20e
5.36 19
22 5.78 5.55 23
23 5.55 5.77 22
24 2.28 0.91 24a
3.47 25
24a 0.91 2.28 24
25 3.47 2.28 24
26 1.60 0.93 26a
26a 0.93 1.48^1.54 27
1.60 26
27 1.48^1.54 0.95 28
0.93 26a
28 0.95 1.48^1.54 27
1P 4.83 1.92 2Pa
2Pe 2.14 1.92 2Pa
4.27 3P
2Pa 1.92 2.14 2Pe
4.27 3P
4.83 1P
3P 4.27 1.92 2Pa
2.14 2Pe
4P 3.29 4.19 5P
5P 4.19 1.27 6P
3.29 4P
6P 1.27 4.19 5P
Table 13 (continued)
Position 1H 1H Position
1Q 5.18 1.71 2Qa
2Qe 2.23 1.71 2Qa
3.95 3Q
2Qa 1.71 2.23 2Qe
3.95 3Q
5.18 1Q
3Q 3.95 1.71 2Qa
2.23 2Qe
3.19 4Q
4Q 3.19 3.67 5Q
3.95 3Q
5Q 3.67 1.30 6Q
3.19 4Q
6Q 1.30 3.67 5Q
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about 25 ml material), respectively. The plates were chopped and
extracted four times with ethyl acetate and three times with meth-
anol, before evaporating the combined extracts of each strain to
dryness. The avermectins A1a2 and A1a3 were separated out of
the crude extracts from avermectin A1a1 by semi-preparative
HPLC (system 4, see below). By using the same semi-preparative
HPLC treatment a second time, puri¢ed avermectin A1a1 was
obtained. Avermectin A1a2 was separated from a third com-
pound by preparative thin-layer chromatography (silica gel 60/
F254 TLC plates, E. Merck, Darmstadt, Germany; ethyl acetate:
methylene chloride:acetonitrile 50:100:8) and extracted from
the scraped o¡ silica gel by ethyl acetate and methanol, before
purifying the compounds on Sephadex LH20 (Pharmacia; solvent
methanol). The third compound also showed the typical avermec-
tin UV-spectrum and the mass determined to be the same as that
of avermectins A1a1 and A1a2. Avermectin A1a3 was puri¢ed
out of its crude extract by two semi-preparative HPLC steps
using system 2. We received 0.5 mg/l of avermectin A1a1, 0.4
mg/l avermectin A1a2, and 0.3 mg/l for the third avermectin
derivative from both S. lividans K4^114/pWHM2106 (avrBED-
CIGF, vavrH) and S. lividans K4^114/pWHM2111 (avrBEDCGF,
vavrHI) as well as 1.1 mg/l avermectin A1a3 from S. lividans K4^
114/pWHM2130 (avrBEDCIHG, vavrF).
5.8. Avermectin A1a1
M = 859.06 (C47H70O14); ESI-MS pos. mode m/z : 881.5
[(M+Na)] ; MP: 171‡C; IR (KBr): 9= 3487, 2994, 2935, 2866,
1381, 1368, 1365, 1157, 1148, 1125, 1065, 1055, 1030, 991, 975,
956, 803, 615, 470, 419, 393 cm31 ; UV (methanol) max nm:
236.0, 243.5, 252.7; Rf : 0.17 (ethyl acetate:methylene chloride:
acetonitrile 50:100:8; Rf avermectin A1a aglycone 0.67); Rf
17.49 min (analytical HPLC system; Rf avermectin A1a aglycone
12.95 min); NMR data see Tables 4^8.
5.9. Avermectin A1a2
M = 859.06 (C47H70O14); ESI-MS pos. mode m/z : 881.5
Table 16
H,H-COSY couplings of avermectin A1a3 in methanol-d4 (N, relative to
TMS)
Position 1H 1H Position
2 3.21 1.78 4a
3 5.47 1.78 4a
4a 1.78 3.21 2
5.47 3
8a 4.60^4.64 5.80 9
9 5.80 4.60^4.64 8a
10 5.86 5.65 11
11 5.65 2.60 12
5.86 10
12 2.60 1.12 12a
5.65 11
4.09 13
12a 1.12 2.60 12
13 4.09 2.60 12
14a 1.53 5.24 15
15 5.24 1.53 14a
2.26 16
16 2.26 5.24 15
3.89 17
17 3.89 2.26 16
18e 1.92 0.86 18a
18a 0.86 1.92 18e
19 5.04 1.35 20a
2.19 20e
20e 2.19 1.60 20a
5.04 19
20a 1.35 2.19 20e
5.04 19
22 5.75 5.54 23
23 5.54 5.75 22
24 2.29 0.92 24a
3.46 25
24a 0.92 2.29 24
25 3.46 2.29 24
26 1.65 0.94 26a
26a 0.94 1.65 26
27 1.48^1.58 0.99 28
28 0.99 1.48^1.58 27
1P 4.38 1.60 2Pa
2Pe 2.14 1.60 2Pa
3.48 3P
2Pa 1.60 2.14 2Pe
4.38 1P
3P 3.48 2.14 2Pe
2.91 4P
4P 2.91 3.48 3P
3.14 5P
5P 3.14 1.26 6P
2.91 4P
6P 1.26 3.14 5P
Table 15
HMBC couplings of avermectin A1a3 in methanol-d4 (N, relative to
TMS)
Position 1H 13C Position
4a 1.78 121.2 3
135.2 4
5a 3.46 78.2 5/6
12a 1.12 84.0 13
139.0 11
14a 1.53 84.0 13
119.2 15
137.2 14
18a 0.86 69.9 19
70.1 17
20a 1.35 69.9 19
97.3 21
22 5.75 97.3 21
24a 0.92 31.8 24
75.9 25
136.6 22
26a 0.94 28.5 27
36.6 26
75.9 25
28 0.99 28.5 27
36.6 26
4P 2.91 72.5 3P
6P 1.26 73.2 5P
78.7 4P
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[(M+Na)] ; mp: 169‡C; IR (KBr): X= 3480, 2985, 2930, 2860,
1376, 1364, 1360, 1150, 1141, 1119, 1060, 1046, 1022, 985, 967,
950, 794, 607, 467, 415, 393 cm31 ; UV (methanol) max nm:
236.0, 243.5, 252.7; Rf : 0.15 (ethyl acetate:methylene chloride:
acetonitrile 50:100:8; Rf avermectin A1a aglycone 0.67); Rf
18.49 min (analytical HPLC system; Rf avermectin A1a aglycone
12.95 min); NMR data see Tables 4, 5, 9^14.
5.10. Avermectin A1a3
M = 728.92 (C41H60O11); ESI-MS pos. mode m/z : 751.6
[(M+Na)] ; mp: 140‡C; IR (KBr): X= 3420, 2981, 2921, 2839,
1722, 1625, 1370, 1355, 1328, 1154, 1146, 1115, 1062, 990, 902,
795, 586, 468, 417, 391 cm31 ; UV (methanol) max nm: 236.0,
243.5, 252.7; Rf : 0.27 (ethyl acetate:methylene chloride:acetoni-
trile 50:100:8; Rf avermectin A1a aglycone 0.67); Rf 14.24 min
(analytical HPLC system; Rf avermectin A1a aglycone 12.95
min); NMR data see Tables 4, 5, 15 and 16.
5.11. HPLC
A Waters HPLC system (controlled by Millenium32 software,
v. 3.5) with two pumps (models 510 and 515), pump control
module, and photodiode array detector (model 996) was used.
For analytical purposes we used a Nova-Pak C18 60A 4 Wm
(150U3.9 mm) column with 1.0 ml/min £ow speed and the fol-
lowing solvent system: solvent A = water; solvent B = methanol;
£ow rate of 1.0 ml/min, ambient temperature, 30% A:70% B to
10% A:90% B (linear gradient, curve 6, 0^20 min); 10% A:90% B
to 100% B (concave gradient, curve 9, 20^25 min); 100% B to
30% A:70% B (curve 9, 25^30 min). For semi-preparative frac-
tioning several di¡erent solvent gradients were developed, using
water as solvent A, methanol as solvent B and a £ow rate of 2 ml/
min: System 1: 30% A:70% B to 100% B (curve 6, 0^40 min);
100% B to 30% A:70% B (curve 9, 40^50 min). System 2: 30%
A:70% B to 40% A:60% B (curve 6, 0^60 min); 40% A:60% B to
30% A:70% B (curve 6, 60^62 min). System 3: 30% A:70% B to
10% A:90% B (curve 6, 0^40 min); 10% A:90% B to 100% B
(curve 6, 40^45 min); 100% B to 30% A:70% B (curve 6, 45^50
min). System 4: 30% A:70% B to 12.5% A:87.5% B (curve 6, 0^
110 min); 12.5% A:87.5% B to 100% B (curve 6, 110^115 min);
100% B to 30% A:70% B (curve 6, 115^120 min). For both
analytical and semi-preparative work Sentry Guard Columns
Nova-Pak C18 60A 4 Wm (20U3.9 mm) were used in addition.
5.12. Additional instruments
The 1H and 13C NMR spectra were recorded in methanol and
chloroform at 500 and 125.71 MHz, respectively. The di¡erent
structures were elucidated by using 1D spectra and 2D homo-
and heteronuclear correlation experiments (1H, 13C, DEPT,
H,H-COSY, HMQC, HSQC, HMBC, 2D-NOESY, 1D-NOESY,
1D-TOCSY) recorded on a Varian Unity-500. Electrospray ion-
ization mass spectrometry (ESI-MS, University of Wisconsin Bio-
technology Center) and matrix-assisted laser desorption/ioniza-
tion mass spectrometry (HR-MALDI-FT-MS, Mass Consortium,
San Diego, CA, USA) was used to determine the mass. IR-spec-
tra were recorded on a Perkin-Elmer Infrared Spectrometer 599
B. A Unimelt Thomas Hoover Capillary Melting Point Appara-
tus was used to determine melting points and PCR ampli¢cation
was performed in a thermal cycler Perkin-Elmer Cetus model 480.
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